Successful Antiviral Treatment with Direct-Acting Antivirals for Hepatitis C Virus Infection during Peritransplant Period in a Kidney Transplant Recipient

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left"></td><td class="align_center">Glecaprevir/pibrentasvir</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Tacrolimus</td><td class="align_center">Orange</td></tr><tr><td class="align_left">Mycophenolate</td><td class="align_center">Green</td></tr><tr><td class="align_left">Methylprednisone</td><td class="align_center">Green</td></tr><tr><td class="align_left">Prednisone</td><td class="align_center">Green</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Degree of safety of coadministration of glecaprevir/pibrentasvir and immunosuppressants (red: do not coadminister; orange: potential interaction; yellow: potential weak interaction; green: no interaction expected) [<a href="/journals/crit/2021/1948560/#B10" target="_blank">10</a>].</div>

Case Reports in Transplantation

tab1

Table 1

Table 1: Successful Antiviral Treatment with Direct-Acting Antivirals for Hepatitis C Virus Infection during Peritransplant Period in a Kidney Transplant Recipient 

Table 1 | Successful Antiviral Treatment with Direct-Acting Antivirals for Hepatitis C Virus Infection during Peritransplant Period in a Kidney Transplant Recipient 